Ms. Xin Xin | Cancer Biomarkers | Best Researcher Award

Posted on by Pencis

Ms. Xin Xin | Cancer Biomarkers | Best Researcher Award

Shanghai University of Traditional Chinese Medicine | China

AUTHOR PROFILE

Scopus

šŸ“š EARLY ACADEMIC PURSUITS

Xin Xinā€™s academic journey is rooted in the integration of Traditional Chinese Medicine (TCM) with Western medicine, particularly focusing on reproductive health and gynecology. He obtained a Bachelor of Science in Chinese Medicine from Shandong University of Traditional Chinese Medicine. His academic foundation continued to expand as he pursued an MD in Gynecology of Traditional Chinese Medicine, further honing his expertise in reproductive diseases. Xin is currently working towards his PhD in Clinical Chinese Medicine Integrated with Western Medicine at Shanghai University of Traditional Chinese Medicine, under the guidance of Advisor Jinfu Zhang.

šŸ’¼ PROFESSIONAL ENDEAVORS

Xin Xinā€™s professional career is centered on bridging the gap between traditional and modern medical approaches. He is particularly involved in the clinical and mechanistic research of reproductive diseases, with a primary focus on polycystic ovary syndrome (PCOS). His work aims to enhance diagnostic methods and treatment approaches through a combined understanding of TCM and Western medicine. Xin has contributed significantly to clinical studies and investigations, with his academic path guided by prominent scholars in the field, including Dr. Fang Lian and Dr. Haicui Wu during his MD program at Shandong University.

šŸ”¬ CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER BIOMARKERS

Xin Xinā€™s research is notable for its emphasis on the pathogenesis, diagnosis, and treatment of reproductive diseases, with a particular focus on PCOS. He has undertaken several groundbreaking projects, one of which explores the expression of long non-coding RNAs (lncRNA) in follicular fluid exosomes of patients with obesity and PCOS using high-throughput sequencing technology. This research represents an effort to better understand the molecular mechanisms behind PCOS and to uncover novel biomarkers for early detection and intervention.

Another area of Xinā€™s research explores the role of Bone Morphogenetic Protein 6 (BMP6) in regulating Pentraxin 3 expression in human granulosa lutein cells in women with PCOS. His studies are pivotal in uncovering molecular markers and pathways that could lead to more effective therapeutic strategies.

šŸŒŸ IMPACT AND INFLUENCE

Xin Xin’s work has garnered attention within the scientific community due to his innovative approach of combining traditional Chinese medicine with Western medical techniques. His research aims to contribute to the development of a more holistic and comprehensive understanding of reproductive diseases. By investigating both the molecular and clinical aspects of PCOS, Xin is pushing boundaries in reproductive health research. His work has the potential to change how clinicians approach the treatment of polycystic ovary syndrome, a condition that affects millions of women worldwide.

šŸ“‘ ACADEMIC CITES

Although his research is relatively recent, Xin Xinā€™s work is beginning to attract attention in the academic community. His publications on the expression of lncRNAs and BMP6 in PCOS are contributing to the growing body of knowledge on this common reproductive disorder. These publications are expected to increase in citations as they influence future studies and clinical approaches. His articles, including ā€œExploring lncRNA expression in follicular fluid exosomes of patients with obesity and polycystic ovary syndromeā€ (2024), and ā€œBone Morphogenetic Protein 6 Induces Downregulation of Pentraxin 3 Expression in Human Granulosa Lutein Cells in Women With Polycystic Ovary Syndromeā€ (2024), are already making a mark in reproductive health research.

šŸŒ± LEGACY AND FUTURE CONTRIBUTIONS

Looking ahead, Xin Xin is poised to continue his impactful contributions to the field of reproductive medicine. With a focus on integrating TCM with Western medical practices, his future research may lead to the development of novel therapeutic modalities for PCOS and other reproductive diseases. He is likely to remain an influential figure in the field of gynecology, particularly in areas that explore the intersections between traditional and modern approaches to healthcare. His research has the potential to influence both clinical practices and medical education, paving the way for new, more integrated methods of treating complex reproductive health conditions.

In the coming years, Xin Xinā€™s work will likely expand into further clinical trials and studies, contributing to the refinement of treatments for women with PCOS, and potentially providing a more personalized and effective approach to reproductive medicine globally.

āœØConclusion:

Xin Xin’s academic and professional journey stands as a testament to the growing importance of integrating traditional and modern medical practices in addressing complex health conditions. His dedicated research in reproductive medicine, particularly focusing on polycystic ovary syndrome (PCOS), has already made valuable contributions to understanding its pathogenesis and improving diagnostic and therapeutic methods. By exploring innovative molecular mechanisms and combining high-throughput sequencing technology with traditional Chinese medicine, Xin is laying the groundwork for a more holistic approach to treating reproductive diseases.

šŸ“ŠšŸ”¬NOTABLE PUBLICATION:
  • Reproductive outcomes of dual trigger with combination GnRH agonist and hCG versus trigger with hCG alone in women undergoing IVF/ICSI cycles: a retrospective cohort study with propensity score matching
    • Authors: Dong, L., Lian, F., Wu, H., Yu, X., Xin, X.
    • Journal: BMC Pregnancy and Childbirth
    • Year: 2022

 

  • The effect of large follicle puncture and aspiration on the outcomes of IVF-ET in patients with asynchronized follicles under the long GnRH-a protocol: a retrospective cohort study
    • Authors: Wang, Y., Pang, C., Wu, H., Xin, X., Lian, F.
    • Journal: BMC Pregnancy and Childbirth
    • Year: 2023

 

  • Effect of human chorionic gonadotropin injection before frozen-thawed embryo transfer: A retrospective cohort study
    • Authors: Xin, X., Dong, L., Guan, L., Li, J., Lian, F.
    • Journal: Medicine (United States)
    • Year: 2023

 

  • Clinical Efficacy and Mechanism of Erzhi Tiangui Prescription in Treatment of Patients with Repeated Implantation Failure of Kidney Deficiency Syndrome Based on sPD-1 and Th17/Treg Cytokines
    • Authors: Wang, Y., Pang, C., Wu, H., Xin, X., Lian, F.
    • Journal: Chinese Journal of Experimental Traditional Medical Formulae
    • Year: 2023

 

  • Total knee arthroplasty in patients with Klippel Trenaunay syndrome and knee osteoarthritis: A case report and a literature review
    • Authors: Li, J., Lv, G., Han, Z., Xin, X.
    • Journal: Medicine (United States)
    • Year: 2024

Dr. Stavros Melemenidis | Micrometastases | Best Researcher Award

Posted on by Pencis

Dr. Stavros Melemenidis | Micrometastases | Best Researcher Award

Stanford University School of Medicine | United States

Author Profile

Scopus

Orcid id

šŸ“š Biography: Dr. Stavros Melemenidis

šŸŽ“ Education

  • DPhil in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2010-2015)
    • Mentors: Prof. Nicola Sibson, Prof. Ruth Muschel
    • Thesis: Development of molecular targeted imaging methods for the detection of lung metastasis and angiogenesis
  • M.Sc. in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2009-2010)
  • M.Sc. in Radiometrics – University of Liverpool, Dept. Physics, Liverpool, UK (2008-2009)
  • B.Sc. in Physics: Medical Applications – University of Liverpool, Dept. Physics, Liverpool, UK (2005-2008)
  • A.Eng. in PC Systems and Peripheral Equipment – IIEK Neapoleos, Technical College, Thessaloniki, Greece (1998-2000)
  • Cert. Medical Physics – UCLA, Dept. Radiation Oncology, Los Angeles, CA, USA (2022-2023)

šŸ¢ Current Position

  • Director of Pre-clinical Radiotherapy – Dept. of Radiation Oncology, Stanford University (Jan 2023-present)
  • Research Scientist – Div. of Radiation Therapy, Stanford University (Feb 2020-present)

šŸ”¬ Research Experience & Skills

  • Stanford University, Dept. Radiation Oncology, Stanford, CA
    • Director of Pre-clinical Radiotherapy Core (Jun 2023-present)
      • Calibration of preclinical orthovoltage irradiators
      • Monthly and annual quality checks for dosimetric consistency
      • Innovation in animal radiation shielding via 3D design and additive manufacturing
    • Basic Life Research Scientist at Div. of Radiation Therapy (Jun 2020-present)
      • Pioneering preclinical ultra-high dose-rate (FLASH) irradiation experiments
      • Specializing in 3D-designed radiation shielding for animal safety
      • Expertise in dosimetry using radiochromic film and ion chambers
      • Development of animal models involving tumor implantation and microsurgical techniques
    • Postdoctoral Fellow (Feb 2016-Jun 2020)
      • Advisor: Edward E. Graves
      • Led development of in vivo mouse tumor models integrating imaging, radiotherapy, and immunotherapy
      • Specialized in ultrasound-guided injection techniques
      • Conducted research into immune cell migration with a focus on macrophage imaging
      • Evaluated radioprotective strategies for healthy tissue through drug development
    • Postdoctoral Fellow at University of Oxford, Dept. Radiation Oncology (Jan 2015-Sep 2015)
      • Advisor: Nicola R. Sibson
      • Designed and evaluated innovative imaging probes for metastasis detection and angiogenesis visualization
      • Developed dual MRI/PET probe for metastasis and MRI probe for angiogenesis
      • Managed international research collaboration with Duke University

šŸ“œ Selected Publications

  • In vivo PET detection of lung micrometastasis by targeting endothelial VCAM-1. Int J Mol Sci, 2024.
  • Multi-institutional audit of FLASH and conventional dosimetry with a 3D-printed anatomically realistic mouse phantom. Int J Radiat Oncol Biol Phys, 2023.
  • Exploring deep learning for estimating the isoeffective dose of FLASH irradiation from mouse intestinal histological images. J Radiat Oncol Biol Phys, 2023.
  • Human enteroids as a tool to study conventional and ultra-high dose rate radiation. Integr Biol (Camb), 2023.
  • Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1. J Clin Invest, 2023.

šŸ† Awards & Honors

  • Recognition of Excellent Research: Aegean Conferences: 12th International Conference on Complement Therapeutics, Rhodes, Greece, 2019
  • Poster Prize: Aegean Conferences: 3rd International Conference for Tumor Microenvironment and Cellular Stress, Greece, Mykonos, 2014

šŸ—£ļø Conference Presentations

  • Oral Presentation: Demonstrating FLASH effectiveness against CONV dose rates, 34th ACRO Summit, Orlando, FL, March 2024
  • Poster Presentation: Anatomically Realistic 3D Printed Mouse Phantom for Multi-Institutional Benchmarking of FLASH and CONV Irradiation, 65th ASTRO Annual Meeting San Diego, USA, Oct 2023

šŸ“ž References

  • Prof. Billy W Loo Jr: Professor of Radiation Oncology (Radiation Therapy), Stanford University School of Medicine
  • Prof. Edward E Graves: Associate Professor of Radiation Oncology and Director of Molecular Imaging Program, Stanford University School of Medicine
  • Prof. Frederick M Dirbas: Associate Professor of Surgery (General Surgery), Stanford University School of Medicine

Dr. Stavros Melemenidis is a distinguished figure in radiation oncology, with a profound impact on preclinical radiotherapy and FLASH irradiation research. His contributions to innovative imaging techniques and his dedication to advancing cancer treatment methodologies are reflected in his extensive publication record and numerous accolades.

šŸ“ŠšŸ”¬Notable Publication:

 

 

 

 

Assist Prof Dr. Juan Yakisich – Cancer Cell Biology – Best Researcher Award

Posted on by Pencis

Assist Prof Dr. Juan Yakisich - Cancer Cell Biology - Best Researcher Award

Hampton University - United States

AUTHOR PROFILE

Google Scholar

Orcid

EARLY ACADEMIC PURSUITS

Juan Sebastian Yakisich, MD, PhD, pursued an interdisciplinary biomedical research path, obtaining his doctoral education at the esteemed Karolinska Institute in Europe, one of the largest and most prestigious medical universities. His early academic pursuits laid the foundation for his expertise in cell & molecular biology, cancer biology & molecular oncology, and pharmacology.

PROFESSIONAL ENDEAVORS

Following his doctoral education, Dr. Yakisich undertook postdoctoral training at the Department of Molecular and Cellular Medicine, Texas A&M University, College Station, TX. His professional journey also included a highly competitive and prestigious research grant from the Swedish Research Council, leading to four additional years as a project leader at the Department of Clinical Neuroscience, Karolinska Institute.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER CELL BIOLOGY

Dr. Yakisich possesses a comprehensive background in cancer cell biology and pharmacology, specializing in cellular and molecular biology, anticancer drug screening, and cancer stem cell biology. His significant contributions include the development of a groundbreaking cancer stem cell model (The stemness phenotype model) applicable to various cancer types, with substantial clinical implications. Additionally, he pioneered effective strategies for anticancer drug screening, addressing limitations in existing programs.

IMPACT AND INFLUENCE

As an oncology researcher, Dr. Yakisich has made a substantial impact, contributing to the understanding and treatment of various cancers, including brain tumors, cervical, lung, and breast cancers. His work has not only shaped research directions but has practical applications in clinical settings, improving the screening of oncology markers and enhancing drug delivery into cancer cells.

ACADEMIC CITES

Dr. Yakisich's academic achievements are reflected in his publication record, including over 60 peer-reviewed original articles and reviews in international leading journals. He has served as a grant and postdoctoral fellowship reviewer for NASA and held editorial and associate board memberships in international peer-reviewed journals such as Frontiers in Pharmacology.

LEGACY AND FUTURE CONTRIBUTIONS HIGHLIGHT

In his tenure at Hampton University, Dr. Yakisich has continued to contribute significantly, publishing over twenty-five peer-reviewed articles and three book chapters. His commitment to education is evident through mentoring and training Master's, PhD, undergraduate, and high school students in multiple countries. Dr. Yakisich emphasizes a commitment to mentor and train underrepresented minorities in basic and translational research, leaving a lasting legacy of diversity and inclusion.

FUTURE CONTRIBUTIONS

Looking ahead, Dr. Yakisich is actively engaged in the development of aptamer-based biomedical tools for identifying oncology markers, pathogen detection and elimination, and drug delivery into cancer cells. His dedication to mentoring and training underscores a commitment to advancing scientific knowledge and fostering the next generation of researchers, ensuring a continued impact on the field of biomedical research.

NOTABLE PUBLICATIONS

A short post reattachment ultra-sensitive window of time in human cancer cells as therapeutic target of prolonged low dose administration of specific compounds. 2024

Two-Step Preparation of Protein-Decorated Biohybrid Quantum Dot Nanoparticles for Cellular Uptake. 2023

Phenotypic Characterization of 2D and 3D Prostate Cancer Cell Systems Using Electrical Impedance Spectroscopy. 2023

Downregulation of DKK-1 and Upregulation of B - Catenin in Cancer Floating Spheroids is Associated with Chemoresistance to Wnt Signaling Pathway Inhibitors. 2022

Translational Gap in Lung Cancer Research. 2022